Comparison of HbA1c and oral glucose tolerance test for diagnosis of diabetes in patients with coronary artery disease
- 497 Downloads
Measurement of glycated hemoglobin A1c (HbA1c) to diagnose diabetes mellitus (DM-2) is recommended by several expert groups. DM-2 occurs very frequently among patients with coronary artery disease (CAD). Therefore, we aimed to investigate the diagnostic strengths of HbA1c and oral glucose tolerance test (OGTT) in detecting latent glucometabolic disturbances among patients with CAD.
Materials and methods
One hundred ninety-nine consecutive patients admitted with CAD were included in this observational study. Fasting plasma glucose as well as HbA1c measurement was performed in all study participants and those without preexisting DM-2 underwent an OGTT.
Patients were subdivided according to their medical history into those with previous DM-2 (n = 37). The remaining 162 patients underwent OGTT, which revealed 39 patients with diabetes (DM-OGTT), 35 with impaired glucose tolerance (IGT), 20 with impaired fasting glucose (IFG) and 68 with normal glucose tolerance (NGT). Using HbA1c resulted in 6.8% DM and 45.6% at risk (HbA1c 5.7–6.4%) diagnosis. OGTT identified 24.1% DM (p = 0.002 compared with HbA1c) and 21.6% IGT patients. Among those with intermediate HbA1c (5.7–6.4%) 26.5% patients were NGT and only 30.9% displayed DM-2 by use of OGTT. Among patients with HbA1c of <5.7%, 44% (n = 31) of patients had disturbed glucose metabolism. Using receiver-operating curve HbA1c cutoff with the highest sensitivity and specificity was found to be 5.8%.
There is a large discordance between OGTT and HbA1c in terms of detecting latent DM-2 in patients with CAD. Measurement of HbA1c could result in lower propensity of DM-2 diagnosis.
KeywordsDiabetes mellitus Coronary artery disease Oral glucose tolerance test Glycated hemoglobin
This work was supported by the Association for the Promotion of Scientific Research in Arteriosclerosis, Thrombosis and Vascular Biology (ATVB).
Conflict of interest
There are neither financial nor non-financial disclosures for all authors to declare.
- 4.Bartnik M, Ryden L, Ferrari R, Malmberg K, Pyorala K, Simoons M, Standl E, Soler–Soler J, Ohrvik J (2004) The prevalence of abnormal glucose regulation in patients with coronary artery disease across Europe. The Euro Heart Survey on diabetes and the heart. Eur Heart J 25:1880–1890PubMedCrossRefGoogle Scholar
- 9.World Health Organization and International Diabetes Federation (1999) Definition, diagnosis and classification of diabetes mellitus and its complications. World Health Organization, GenevaGoogle Scholar
- 12.Lorenzo C, Wagenknecht LE, Hanley AJ, Rewers MJ, Karter AJ, Haffner SM (2010) Hemoglobin A1c between 5.7 and 6.4% as a marker for identifying pre-diabetes, insulin sensitivity and secretion, and cardiovascular risk factors: the insulin resistance atherosclerosis study (IRAS). Diabetes Care 33:2104–2109PubMedCrossRefGoogle Scholar
- 16.Boden WE, O’Rourke RA, Teo KK, Hartigan PM, Maron DJ, Kostuk WJ, Knudtson M, Dada M, Casperson P, Harris CL, Chaitman BR, Shaw L, Gosselin G, Nawaz S, Title LM, Gau G, Blaustein AS, Booth DC, Bates ER, Spertus JA, Berman DS, Mancini GB, Weintraub WS (2007) Optimal medical therapy with or without PCI for stable coronary disease. N Engl J Med 356:1503–1516PubMedCrossRefGoogle Scholar
- 19.Boavida JM, Gardete-Correia L, Massano-Cardoso S, Mesquita C, Raposo JF (2010) Hemoglobin A1c in a population with pre-diabetes, diagnosed and previously undiagnosed diabetes. Diabetologia 53:S87Google Scholar
- 20.Cosson E, Nguyen M, Hamo Tchatchouang E, Banu I, Chiheb S, Valensi P (2010) Diagnosis of abnormal glucose levels in patients at high risk for the development of diabetes: a comparison of the oral glucose tolerance test and measurement of HbA1c following the American Diabetes Association recommendations 2010. Diabetologia 53:S87Google Scholar
- 21.Delgado E, De la Hera JM, Lozano I, Hernandez E, Vegas JM, Fernandez-Cimadevilla C, Torres F, Carro A, Bayon J, Garcia-Ruiz JM, Avanzas P (2010) Detection of diabetes in coronary artery disease: oral glucose tolerance test or glycated haemoglobin and fasting plasma glucose? Diabetologia 53:S159Google Scholar
- 22.Koehler C, Henkel E, Schaper F, Hanefeld M (2010) The HbA1c cut points for detecting type 2 diabetes and prediabetes in a risk population—is this the right way? Diabetologia 53:S158Google Scholar
- 25.Preiss D, Welsh P, Murray HM, Shepherd J, Packard C, Macfarlane P, Cobbe S, Ford I, Sattar N (2010) Fasting plasma glucose in non-diabetic participants and the risk for incident cardiovascular events, diabetes, and mortality: results from WOSCOPS 15-year follow-up. Eur Heart J 31:1230–1236PubMedCrossRefGoogle Scholar
- 26.Ryden L, Standl E, Bartnik M, Van den Berghe G, Betteridge J, de Boer MJ, Cosentino F, Jonsson B, Laakso M, Malmberg K, Priori S, Ostergren J, Tuomilehto J, Thrainsdottir I, Vanhorebeek I, Stramba-Badiale M, Lindgren P, Qiao Q, Priori SG, Blanc JJ, Budaj A, Camm J, Dean V, Deckers J, Dickstein K, Lekakis J, McGregor K, Metra M, Morais J, Osterspey A, Tamargo J, Zamorano JL, Deckers JW, Bertrand M, Charbonnel B, Erdmann E, Ferrannini E, Flyvbjerg A, Gohlke H, Juanatey JR, Graham I, Monteiro PF, Parhofer K, Pyorala K, Raz I, Schernthaner G, Volpe M, Wood D (2007) Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary. The task force on diabetes and cardiovascular diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD). Eur Heart J 28:88–136PubMedCrossRefGoogle Scholar